Author:
Grimm Alizée J.,Kontos Stephan,Diaceri Giacomo,Quaglia-Thermes Xavier,Hubbell Jeffrey A.
Publisher
Springer Science and Business Media LLC
Reference40 articles.
1. Michael, M., Shimoni, A. & Nagler, A. Recent compounds for immunosuppression and experimental therapies for acute graft-versus-host disease. Isr. Med. Assoc. J. 15, 44–50 (2013).
2. Herold, K. C. et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 62, 3766–74 (2013).
3. Pescovitz, M. D. et al. Rituximab, B-lymphocyte depletion and preservation of beta-cell function. N. Engl. J. Med. 361, 2143–52 (2009).
4. Kontos, S., Grimm, A. J. & Hubbell, J. A. Engineering Antigen-Specific Immunological Tolerance. Curr. Opin. Immunol. 35, (2015).
5. Akdis, C. A. & Akdis, M. Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens. World Allergy Organ. J. 8, 17 (2015).
Cited by
72 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献